
Detalimogene Demonstrates Durability in NMIBC, Supporting BLA Submission
Key Takeaways
- Extended follow-up in 120 efficacy-evaluable patients yielded a 56% any-time CR and a 24% 12-month landmark CR in CIS ± papillary high-risk BCG-unresponsive NMIBC.
- Durability metrics strengthened, with an estimated 43% achieving ≥12-month DOR and median CR duration improving to 10.1 months with 12.0-month median follow-up in responders.
Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive NMIBC, supporting a planned BLA submission by year-end 2026.
Updated findings from the pivotal cohort 1 of the phase 2 LEGEND trial (NCT04752722) demonstrated improvements across efficacy measures with detalimogene voraplasmid in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC).1
The findings reflect additional follow-up from 125 patients enrolled in cohort 1, which includes patients with carcinoma in situ (CIS), with or without concomitant papillary disease. Efficacy analyses were based on 120 evaluable patients as of the October 29, 2026, data cutoff. The complete response (CR) rate at any time was 56% (95% CI, 47%-65%), compared with 54% in the
The preliminary Kaplan-Meier duration of response (DOR) estimate of at least 12 months, a key secondary end point, increased from 25% to 43% (95% CI, 30%-55%). Median duration of CR also improved, increasing from 8.6 to 10.1 months (95% CI, 7.5 months-not estimable). Median follow-up among responders increased from 9.2 to 12.0 months.
Additional disease control findings showed that 97% of efficacy-evaluable patients remained free from progression to muscle-invasive or metastatic bladder cancer, defined as T2 or greater disease. All responders remained free from progression to T2 or greater disease. Additionally, 86% of all efficacy-evaluable patients and 96% of responders remained free from cystectomy.
The sponsor plans to use these results to support a biologics license application (BLA) to the FDA, with submission expected to begin by the end of 2026 and completion anticipated in the first half of 2027.
“For patients with high-risk BCG-unresponsive NMIBC, we need therapies that provide meaningful and durable disease control while minimizing treatment-related toxicity and burden,” Ashish M. Kamat, MD, of The University of Texas MD Anderson Cancer Center and LEGEND trial principal investigator, stated in a news release. “The updated LEGEND data are encouraging, demonstrating clinically meaningful antitumor activity with a favorable tolerability profile. Combined with its straightforward administration and handling requirements, detalimogene has the potential to become a valuable addition to our bladder-preserving treatment options, particularly in community urology practices where ease of administration and practical considerations can influence treatment selection.”
About Detalimogene and LEGEND
Detalimogene is an investigational nonviral gene therapy administered intravesically. The treatment is intended to stimulate a localized antitumor immune response in the bladder and was developed using enGene's Dually Derivatized Oligochitosan platform. The therapy, which holds
The LEGEND trial is an ongoing, multicenter, open-label, phase 1/2 study evaluating the safety and efficacy of intravesical detalimogene in patients with high-risk NMIBC.2 The phase 1 portion evaluated dose escalation to establish the recommended phase 2 dose, while the phase 2 portion includes multiple patient cohorts, including patients with BCG-unresponsive NMIBC and CIS (cohort 1).
Patients in cohort 1 receive intravesical detalimogene in 12-week treatment cycles for up to 4 cycles. Patients who achieve a CR following treatment may receive up to 8 additional maintenance cycles. The primary end points of the phase 2 portion include CR rate at week 48 and safety, with secondary end points including progression-free survival and DOR.
Safety Profile
Detalimogene demonstrated a favorable tolerability profile in the safety population of 125 patients. Overall, 59% experienced at least 1 treatment-related adverse event (TRAE), most of which were grade 1 or 2. The most frequently reported TRAEs were fatigue (21%), dysuria (16%), pollakiuria (16%), bladder spasm (13%), micturition urgency (13%), and urinary tract infection (10%).
Grade 3 TRAEs occurred in 4% of patients, while 2% experienced serious TRAEs. No grade 4 or 5 TRAEs were reported. TRAEs leading to treatment discontinuation and dose interruption occurred in 1% and 4% of patients, respectively.
Regulatory Path and Next Steps
Following a pre-BLA meeting with the FDA, the sponsor reported alignment with the agency on key components of the planned submission, including the efficacy-evaluable patient population. The company expects to initiate the BLA submission by year-end 2026 and complete it during the first half of 2027, with potential FDA approval in 2027.
Further data are anticipated from another LEGEND cohort evaluating detalimogene in combination with a surfactant bladder rinse, with an update expected in mid-2027.
REFERENCES
1. enGene to Initiate a BLA Submission for Detalimogene by Year End and Reports New Data from LEGEND Trial Pivotal Cohort 1 in BCG-Unresponsive NMIBC. News release. enGene. November 11, 2026. Accessed November 13, 2026. https://tinyurl.com/46mxhez6
2. LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve. ClinicalTrials.gov. Updated August 7, 2026. Accessed November 13, 2026. https://clinicaltrials.gov/study/NCT04752722
Related to this article








